Data show antibody candidates bind toxic forms
of tau
and inhibit its propagation in a cellular
model
TORONTO and CAMBRIDGE, MA, Oct. 17,
2019 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX: PMN)
(OTCQB: ARFXF), a biotechnology company focused on the discovery
and development of antibody therapeutics targeting toxic oligomers
implicated in the development of neurodegenerative diseases,
continues to further develop antibody candidates that have shown
selectivity for the toxic forms of tau. New pre-clinical data show
that these antibody candidates can block the spread of pathogenic
tau aggregate formation in a cellular model. Continued advancement
of ProMIS' dual approach for Alzheimer's disease, which also
includes antibody PMN310 targeting the toxic oligomers of
amyloid-beta, aligns with research indicating that both misfolded
proteins play a major role in disease progression and represent
highly validated targets for therapy.
ProMIS announced its tau program in May
2019 when it identified several novel antibody candidates
that preferentially bind toxic forms of tau. Pre-clinical data now
show that these candidates can block the formation of pathogenic
tau aggregates in a cellular model. ProMIS leveraged its
proprietary drug discovery and development platform to identify
conformational epitopes on misfolded tau and generate, evaluate and
advance tau antibody candidates, demonstrating the platform's
capacity for producing high-quality antibody candidates rapidly and
cost-effectively.
"The misfolded, toxic forms of tau and amyloid-beta are the two
most validated targets in Alzheimer's therapy development," said
Elliot Goldstein, MD, President and
CEO of ProMIS Neurosciences. "While addressing Alzheimer's will
require a multifactorial approach, selective targeting of
misfolded, toxic forms of both tau and amyloid-beta remains one of
the most promising therapeutic strategies for Alzheimer's disease.
We will continue to strengthen our programs, offering the critical
one-two punch needed for a disease-modifying therapy, while
simultaneously seeking ways to leverage emerging biomarkers to
improve the success and speed of future clinical development."
To learn more about the search for therapies for Alzheimer's,
Parkinson's and other neurodegenerative diseases, listen to the
podcast, Saving Minds, at iTunes or Spotify.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc.
is a development stage biotechnology company focused on discovering
and developing antibody therapeutics selectively targeting toxic
oligomers implicated in the development and progression of
neurodegenerative diseases, in particular Alzheimer's disease (AD),
amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD).
The Company's proprietary target discovery platform is based on the
use of two complementary thermodynamic, computational discovery
engines – ProMIS and Collective Coordinates – to predict novel
targets known as Disease Specific Epitopes on the molecular surface
of misfolded proteins. Using this unique precision approach, the
Company is developing novel antibody therapeutics for AD, ALS and
PD. ProMIS is headquartered in Toronto,
Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on
the Toronto Stock Exchange under the symbol PMN, and on the OTCQB
Venture Market under the symbol ARFXF.
Visit us at www.promisneurosciences.com, follow us on Twitter
and LinkedIn
The TSX has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release. This
information release contains certain forward-looking information.
Such information involves known and unknown risks, uncertainties
and other factors that may cause actual results, performance or
achievements to be materially different from those implied by
statements herein, and therefore these statements should not be
read as guarantees of future performance or results. All
forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently
available to it as well as other factors. Readers are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. Due to risks and
uncertainties, including the risks and uncertainties identified by
the Company in its public securities filings, actual events may
differ materially from current expectations. The Company disclaims
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/promis-neurosciences-advances-alzheimers-disease-program-targeting-neurotoxic-forms-of-tau-300940141.html
SOURCE ProMIS Neurosciences Inc.
